How can a variety of experimental therapies improve human health?

"!-- webeditor:page title" -- In this article, several important research results have been compiled to explain how scientists can use a variety of experimental therapies to improve human health? Share it with everyone! Photo Credit: National Institute of Allergy and Infection Diseases, NIH 1: Cell Host Microbe! Experimental vaccines may be effective in preventing SARS-CoV-2 infections! doi:10.1016/j.chom.2020.07.018 Recently, an article published in the international magazine Cell Host and Microbe entitled "Replication-competent vesicular stomatitis virus vaccine vector protects againST SARS-CoV-2-mediated" In a study by Pathogenesis in mice, scientists from the University of Washington School of Medicine and others said an experimental vaccine could effectively prevent pneumonia in mice infected with the SARS-CoV-2 virus, which is made from a mild virus that genetically modifies to carry key genes from the SARS-CoV-2 virus.
researcher Michael S. Diamond says that unlike other vaccines being developed, the new vaccine is made from a virus that can spread only in the body, which means it appears to induce a strong immune response from the body, which, because of its replicancy, can only be used in the laboratory. High levels of reproduction and growth make it easy to scale up and be more effective than some other vaccine candidates, and although the researchers are showing only proof of concept, this study seems to be very much a game-changer, with candidate vaccines currently being tested in other animal model bodies and later or soon entering human clinical trials.
. Lancet Infect Dis: Clinical trials of experimental antimalarial drugs have been successful: 10.1016/S1473-3099 (19) 30611-5 Recently, researchers at St. Jude Children's Research Hospital demonstrated good resistance to a quick-acting antimalarial compound in the first clinical trial, as well as promising antimalarial effects, the results of which were published in the journal Lancet Infectiouss.
"The results support the further development of the compound SJ733 as an active ingredient in a combined antimalarial treatment," said author Dr. Aditya Gaur.
" Researchers are currently exploring ways to increase and/or extend the blood concentration of SJ733 to maximize its efficacy in patients.
malaria is an infectious disease caused by malaria parasites, transmitted by infected mosquitoes and destroyed by red blood cells.
disease remains the world's main cause of disease and death, and young children are among the most vulnerable.
artemisinin-based combination therapy is currently being used as a first-line treatment for malaria.
But its success rate is being influenced by emerging resistance Two NEJM papers show that the experimental new crown vaccine mRNA-1273 has a promising doi:10.1056/NEJMoa2024671 In a new study, National Allergy and Researchers at the Institute of Infectious Diseases (NIAID) reported that two experimental vaccines to prevent coronavirus disease (COVID-19) in 2019 induced a strong immune response and quickly controlled the coronavirus in the upper and lower respiratory tracts of rhesus monkeys exposed to SARS-CoV-2, the study was published in the journal NEJM.
vaccine, called mRNA-1273, was developed by scientists at the NIAID Vaccine Research Center and Moderna in Cambridge, Massachusetts.
the results of this animal study complement the preliminary results of a recently reported phase 1 clinical trial sponsored by NIAID using mRNA-1273.
the vaccine candidate is produced by Moderna.
( 4) Nat Cancer: Special experimental drugs or heart damage effects from the chemotherapy drug doi:10.1038/s43018-020-0039-1 Commonly used chemotherapy drugs doi:10.1038-0039-1 Doo-stars tend to damage the heart muscle, sometimes It can also lead to severe or fatal heart failure, and in a recent study published in the international journal Nature Cancer, scientists from institutions such as the Albert Einstein College of Medicine studied zebrafish and mice and found that the experimental drug BAI1 may be effective in suppressing the damage to the heart caused by dorothal stars without reducing their anti-cancer effects.
in addition to providing a way to suppress domoxicity," drugs such as BAI1 may also help tumor researchers use domobis at higher cumulative doses and treat cancer more effectively in a coalition with other cardiotoxic drugs, said Richard N. Kitsis, M.D.
The incidence of heart damage caused by dolubyns is highest in specific cancer groups, including the elderly, especially those who already have heart disease or risk factors for heart disease; children with difficulty treating cancer, such as sarcoma, who usually need to be treated with high doses of dosodles; patients who receive multiple doses of relapse cancer; and those who receive other heart toxicity treatments, such as radiotherapy.
: Sci Trans Med: Experimental drugs help treat triple-negative breast cancer doi:10.1126/scitranslmed.aaw8275 Recently, researchers from vanderbilt-Ingram Cancer Center found that MYCN protein played an important role in triple-negative breast cancer (TNBC) and identified possible interventions that could be used in further clinical studies.
Though there is currently no direct-targeting treatment for MYCN proteins for TNBC, researchers from Pietenpol Labs have found that BET inhibitors are effective against TNBC in model systems that over-express MYCN, especially when combined with inhibitors from another known cancer gene, MEK.
MYCN is a well-known cancer gene that works as the cancer worsens, but is usually only associated with neuroendocrine cancer.
!--/ewebeditor:page--!--webeditor:page-title" -- the study, published in the journal Science Translational Medicine, laid the groundwork for a potential treatment for TNBC targeting the MYCN cancer gene.
TNBC is a particularly difficult breast cancer to treat.
TNBC accounts for about 15 percent of breast cancer, it accounts for 25 percent of all breast cancer-related deaths.
treatment options for many patients are still limited to chemotherapy.
Photo Source: Salk Institute( 6) A new experimental immunotherapy or promising treatment for acute myeloid leukemia News Read: Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for The Treatment of Acute Myeloid Leukemia Recently, the 60th Annual American Society of Hematology in San Diego At the conference, scientists from the Lineberger Center for Integrated Cancer Research at the University of North Carolina identified a new method that could target acute myeloid leukemia subtypes using chimeric antigen-subject (CAR) T-cell therapy, which genetically modifies the body's own immune cells to identify and target cancer.
researchers demonstrated the results of their preclinical trial, which used CAR-T cells to directly target potential targets B7-H3, which is present on the surface of specific types of acute myeloid leukemia cells, and believe they can genetically engineer the patient's own normal white blood cells to form CAR-T cells and effectively kill leukemia cells.
M.D. Eben Lichtman said acute myeloid leukemia is the most common type of acute leukemia in adults, patients with poor prognosis, only a quarter of patients can survive more than five years after diagnosis, now CAR-T cell therapy has been able to successfully treat acute lymphoblastic leukemia, but the treatment is not effective treatment of acute myeloid leukemia, in part because acute myeloid leukemia cells do not have an effective target.
:7 Cancer Cell: Experimental therapy helps treat three-negative breast cancer doi:10.1016/j.ccell.2018.11.016 By addressing both cancer growth mechanisms simultaneously, an experimental treatment reduced the spread of triple-negative breast cancer in mouse studies.
the study was published January 3 in the journal Lancer Cell.
study found that a drug called Tinagl1, based on naturally occurring proteins, blocks the growth of breast cancer cells and the movement of tumors from primary sources.
-negative breast cancer is a highly invasive cancer, accounting for 12 to 17 percent of all breast cancer cases.
its name comes from a lack of three prominent biological targets - estrogen-like (ER), progesterone-like (PR) and human skin growth factor-2 (HER2).
patients with triple-negative breast cancer had high recurrence rates and fewer treatment options, as well as the likelihood that the cancer would be resistant to treatment.
this leads to a poor overall prognostic prognosticity of the patient.
: The new experimental HIV vaccine promises to prevent HIV infection doi:10.1016/j.immuni.2018.11.011 In a new study, researchers from the Scripps Institute in the United States designed an experimental vaccine containing this stable SOSIP triumer.
their goal is to see if the vaccine can really protect animal models from infection.
the findings were published online in the journal Immunity.
the researchers tested the experimental vaccine in two groups of monkeys.
previous studies using the same vaccine have shown that some vaccinated monkeys produce lower meso-antibody titration in their bodies, while others produce higher meso-antibody titration after vaccination.
the new study, they selected six monkeys that produced low antibody and six monkeys that produced high antibody and had them vaccinated again.
also studied 12 unvaccinated monkeys as a control group.
the monkeys were then exposed to HIV-like virus, or SHIV, the ape version of HIV, which contains the same viral envelope tripolymer as HIV.
a specific strain called the Tier 2 virus, which is known as SHIV, is difficult to merstify, as is the type of HIV most commonly circulating in the population.
:9 Sci Rep: Experimental drugs can be used to treat hair loss doi:10.1038/s41598-018-28663-9 Recently, researchers from Johns Hopkins University successfully used a class of experimental drugs to cure skin allergies and hair loss symptoms caused by a high-fat diet.
researchers say the compound inhibits the production of glycolipids, which make up the skin and cell membranes.
current studies have shown that mice are more likely to develop symptoms such as hair bleaching, hair and dermatitis after receiving a high-fat diet, which can be alleviated by feeding medications.
the results, the researchers say this does not mean the same applies to humans, and there is no evidence that the compound is safe at human levels.
but the findings do offer new ideas for treating symptoms such as hair loss and dermatitis.
results, published in the latest issue of the Journal of Scientific Reports, need further trial validation, but our results suggest that this drug could be used in the future to treat skin diseases such as psoriasis, which can be used aggressively to treat wound enlargement caused by diabetes or surgery.
: Scientists identify molecular targets for experimental anti-aging drugs promising to enter clinical trials in Alzheimer's patients Doi:10.1111/acel.12715 An experimental drug called J147 may be a modern, endemic drug, and studies have shown it to be effective in treating Alzheimer's disease. Scientists are already ready to use the drug for human clinical trials, and in a recent study published in the international journal Age Cell, researchers from the Salk Institute uncovered the molecular mechanisms by which J147 works, finding that J147 binds to a protein in mitochondrials to promote the younger look of aging cells, mice and fruit flies.
the !-- study, we found a link !-- between the experimental drug J147 and the aging of the body and the onset of Alzheimer's disease; looking for perhaps the target of J147, said researcher Professor Dave Schubert.